Analyst Coverage And RatingsBloom Burton is initiating research coverage of genetic medicine company, PYC Therapeutics, with a BUY rating (Speculative risk).
Clinical Program AdvancementsPYC-003 is now being assessed in a Phase I in healthy volunteers, entering a catalyst-rich period across all of its clinical programs.
Validation And PartnershipsNVS Acquisition of RGLS further validates MOA for potentially best-in-class PYC-003.